

CytomX Therapeutics, Inc.  
Form 8-K  
November 28, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 28, 2017

CYTOMX THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

|                              |                          |                     |
|------------------------------|--------------------------|---------------------|
| Delaware                     | 001-37587                | 27-3521219          |
| (State or Other Jurisdiction |                          | (IRS Employer       |
| of Incorporation)            | (Commission File Number) | Identification No.) |

151 Oyster Point Blvd., Suite 400

South San Francisco, CA 94080

(Address of principal executive offices, including Zip Code)

Edgar Filing: CytomX Therapeutics, Inc. - Form 8-K

Registrant's telephone number, including area code: (650) 515-3185

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01. Other Events.

On November 28, 2017, CytomX Therapeutics, Inc. issued a press release announcing that Bristol-Myers Squibb has received acceptance of the Investigational New Drug application from the U.S. Food and Drug Administration for a CTLA-4-directed Probody™ therapeutic. The full text of the press release is furnished as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibit

No. Description

99.1 Press Release of CytomX Therapeutics, Inc., dated November 28, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 28, 2017 CYTOMX THERAPEUTICS, INC.

By: /s/ Cynthia J. Ladd  
Cynthia J. Ladd  
Senior Vice President and General Counsel